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Editorials
Despite the rise of evidence-based medicine in the late 20th
century,1,2 clinicians must recognise that many aspects of
day-to-day clinical practice, from optimal antibiotic dosing,
fluid resuscitation and nutritional supplementation to seda-
tion and ulcer prophylaxis, have an element of uncertainty
or are open to challenge due to a lack of solid comparative
data. As articulated in the minimum standards for level II
and level III intensive care units by the College of Intensive
Care Medicine in Australia and New Zealand, there is a
need for major hospitals to embrace and support research
as a component of care, including staffing by a full-time ICU
research coordinator.3 The potential benefits of ICU involve-
ment in clinical research are significant. ICUs that undertake
research create a climate of self-analysis, and patients
enrolled into clinical trials may benefit by receiving greater
attention and scrutiny of care.4
Well designed clinical trials, particularly Phase III and
Phase IV trials, represent the pinnacle of evidence for
evaluating new and existing therapies in critical care,5
although not always in isolation from other trials and
sources of evidence.6 The would-be coordinating investiga-
tor, research coordinator and study management commit-
tee face a series of challenges that require careful
preparation and planning, analogous to scaling a mountain.
Our recent experience with a stepwise program of
research7,8 leads us to reflect on challenges in the conduct
of clinical trials and to consider the future of ICU-based
research into therapeutic interventions.9-11
Timelines are critical to success. The lead time for con-
ducting a clinical trial is typically measurable in years.
Demonstrated study feasibility, evidence to support likely
treatment and outcome separation and an informed sample
size are required to attract funding, often necessitating the
need for pilot results.5 Scientific rigour mandates that a
clinical trial must have sufficient power to meet study
objectives. In most cases this requires multicentre collabora-
tion to achieve sufficient participant numbers, typically
numbered in the hundreds for a Phase II trial8,12,13 and in the
thousands for a Phase III or Phase IV trial.14-17 Advance
publication of the statistical analysis plan is an important
step to reduce bias.8,18-23 Although regulatory and govern-
ance requirements are in place for valid reasons, they
represent a daunting series of steps for project managers.24
This approval phase is typically characterised by a series of
delays as documents pass back and forth between sponsor,
site, legal and research governance personnel before finali-
sation. The result is staggered site recruitment and longer
recruitment times. After the study starts, a new series of
challenges emerge, including maintaining adequate recruit-
ment, addressing emergent issues, data monitoring and
ensuring that reporting obligations are met. Our reflections
on lessons learned in clinical trial project management are
summarised in Table 1.
What does the future hold for clinical trials in critical
care? It is safe to say that clinical trials will remain an
integral part of the evaluation of new and existing thera-
peutic interventions. However, we believe increasingly var-
ied combinations of collaborations will continue to emerge
to address logistical issues associated with conducting such
trials, including global networks variably comprising hospi-
tals, research organisations, academia and the commercial
sector. The role of observational data will become increas-
ingly important as larger and more robust registries are
better able to control for potential confounding variables
and deliver generalisable evidence. The result may be
increasingly powerful multicentre observational studies that
reduce the lead time for clinical trials, as hypotheses are
more effectively supported or rejected using existing data
sources. Newer and novel study designs, such as pragmatic
and registry-based randomised trials and cluster ran-
domised trials, may similarly significantly reduce per-patient
time associated with study-specific procedures.25 The first of
such trials in Australia and New Zealand is being planned.
Opt-out consent, minimising data collection through use of
existing data repositories, and reducing variation from
standard practice by block randomisation may successfully
hybridise research with pragmatic clinical care. Adaptive
study designs may similarly improve flexibility and efficiency,
although not without significant practical and statistical
considerations.26 Improved technology and access to user-
friendly electronic case report forms will continue to have
an important role to play, while the use of smartphones,
tablet devices and direct communication between clinical
and research databases holds further promise for efficient
data capture. The trend towards a single ethics review
pathway may reduce some delays,24 but it is unlikely that
many elements of the logistical, regulatory and governance
landscape will change dramatically. Conducting clinical
trials is still a long, at times rewarding and sometimes
frustrating, climb to the summit.
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Table 1. Logistical challenges in conducting investigator-initiated clinical trials
Challenge Recommendations
Limited and highly 
competitive funding 
opportunities
Collaborate with experienced partners.
Ensure funding applications address all aspects (scientific rigour, pilot and feasibility study results, track record).
Consider multiple funding sources, including philanthropic, government and industry.
Plan for top-up funding early on, if required, and consider consequences if successful or unsuccessful.
Ethics approval delays Allow enough time for study planning and NEAF preparation; ensure protocol and study documents have gone 
through peer review before HREC submission.
Be strategic with selection of the lead site for HREC submission; lead sites should have experience and adequate 
research coordinator time; use HRECs where there is an established relationship and familiarity with the 
submission process.
Multiple agreements (eg, 
clinical trial, drug supply, 
subcontractor agreements) 
across multiple jurisdictions
Experienced legal and contract support from the outset is mandatory; don’t operate outside your level of 
experience, and ensure you follow organisational procedure for negotiating agreements.
Speak directly to the decisionmaker when possible; don’t rely on email communication.
Use existing contracts that expedite site negotiation and approval.
Budget and financial 
management
A good business manager is vital to ensure incoming funds and outgoing payments are well managed; review 
the study budget regularly.
Ensure the study budget is as accurate and realistic as possible, with relevant overheads and on-costs built in.
Burden of data collection Limit number of required data fields by careful planning and pilot testing.
Invest in a user-friendly electronic CRF database that is GCP-compliant; spend time developing logic and range 
checks for study variables to minimise errors (eg, autoqueries).
Ensure there is sufficient research staffing at each site in your feasibility assessment.
Drug compounding and 
supply
Consider pharmaceutical industry support.
Provide training materials and videos where sites are involved in drug compounding.
Variable research experience 
at study sites
Ensure the project management team is able to tailor support to the needs of the study site.
Ensure study initiation covers relevant logistical aspects, including GCP.
Establish a clear pathway for communication with the project management team, including after-hours support 
where needed.
Recruitment delays Be realistic with recruitment targets, including conservative (worst-case) projections over the life of the study.
Establish a mechanism to enable the project management team to be informed of study recruitment in real 
time.
Monitor recruitment rates on a regular basis, comparing predicted and actual recruitment; revise predictions 
when there is reason to do so.
Communicate with study sites often and consider recognition or incentives for milestone attainment.
Identify and foster study champions.
Incomplete data Ensure a planned monitoring approach.
Regularly review CRF data during the life of the study.
Establish data entry requirements from the beginning.
Ensure there is a paper CRF that mirrors the electronic CRF.
Develop supporting documents (eg, CRF guidelines and FAQs).
Serious adverse events Accept that SAEs are part of a robust trial and need to be dealt with in a timely manner.
Reinforce reporting requirements via training, CRF prompts, study materials and early site-monitoring visits.
Data monitoring committee Establish clear expectations through a charter.
Data analysis Develop a statistical analysis plan early on and make it available.
Authorship Be clear about authorship early on.
Amendments to the protocol Limit revisions of the protocol to those which are necessary for clarity or success of the study.
Have a strong working relationship with the HREC.
Have a sound knowledge of GCP requirements.
Maintain excellence in record keeping.
Project management team Ensure you have regular project management team and study management committee meetings.
Celebrate successes.
Provide regular communication to sites via newsletters, conferences and other appropriate means.
Study completion Keep everyone motivated.
Use strengths and recognise weaknesses of the study management team for completion.
NEAF = national ethics application form. HREC = human research ethics committee. CRF = case report form. GCP = good clinical practice. FAQs = 
frequently asked questions. SAEs = serious adverse events.
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